CompletedPhase 1NCT01758510

Safety Study of HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis

Studying Amyotrophic lateral sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Hanyang University Seoul Hospital
Principal Investigator
Seung Hyun Kim, M.D., Ph.D
Hanyang University Seoul Hospital
Intervention
HYNR-CS-Allo(genetic)
Enrollment
6 enrolled
Eligibility
25-80 years · All sexes
Timeline
20122017

Study locations (1)

Collaborators

Corestemchemon, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01758510 on ClinicalTrials.gov

Other trials for Amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Amyotrophic lateral sclerosis

← Back to all trials